- There are no upcoming events available at this time.
. A multidisciplinary research team led by Samir M. Parikh, MD, Nephrologist and Principal Investigator at BIDMC, has determined that vitamin B3 has the potential to prevent acute kidney injury. The findings, published in Nature Medicine, bring clinicians one step closer to an accessible and safe therapy for hospitalized patients who may be at risk.
. A recent study has identified a tumor biomarker – a protein called KIM-1 – that could be used to predict the onset of renal cell carcinoma (RCC) up to five before the disease is diagnosed. “The team also found that KIM-1 concentrations were associated with poorer survival,” said lead investigator Rupal Bhatt, MD, PhD, Medical Oncologist at BIDMC. “Further studies are needed, but a sensitive and specific tumor marker that can detect early stage RCC would have strong potential to improve overall survival.”
. Researchers at BIDMC have found that combining two antibiotics that no longer work can create a treatment that’s once again effective against antibiotic-resistant bacteria. “Faced with highly resistant pathogens, clinicians often currently treat with multiple antibiotics without knowing the benefit the combinations may provide,” said senior author of the study James Kirby, MD, Director of the Clinical Microbiology Laboratory at BIDMC. “This study now provides some scientific underpinning for these choices and direction for future investigation.”
An Ancient Medicine Shows New Promise: Arsenic in Combination with an Existing Drug Could Combat Cancer
. Led by Kun Ping Lu, MD, PhD, and Xiao Zhen Zhou, MD, investigators at the Cancer Research Institute at BIDMC have discovered a previously unrecognized mechanism by which arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) work together to combat cancer in human breast cancer cells. In earlier studies, researchers including Pier Paolo Pandolfi, MD, PhD, Director of the Cancer Center and Cancer Research Institute at BIDMC, demonstrated that ATO when used in combination with ATRA was effective against acute promyelocytic leukemia. The team is hopeful that the new discovery, published in Nature Communications, could lead to new treatment strategies for diverse types of cancer.